ClinicalTrials.gg
CompletedNCT03971916Updated Mar 10, 2021

A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers

A Phase 1 interventional study of HBM9161(HL161BKN) and Placebo in Healthy Chinese Volunteers, sponsored by Harbour BioMed (Guangzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Harbour BioMed (Guangzhou) Co. Ltd. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Trial Objective: To investigate the safety, tolerability, PK, and PD following single ascending doses of HBM9161 in healthy Chinese subjects.

Read the detailed description

HBM9161(HL161BKN) is a human monoclonal antibody. HBM9161 targets the neonatal Fc receptor (FcRn) . The neonatal FcRn is a potential therapeutic target for many autoimmune diseases. This Phase I study will evaluate the safety, tolerability, PK, and PD of subcutaneous (SC) doses of HBM9161(HL161BKN) (abbreviated as HBM9161) in healthy Chinese subjects. Up to 24 healthy Chinese subjects will be randomized into the study. For each dose group, 8 subjects will be randomized (6 subjects to HBM9161 group and 2 subjects to placebo group).

This study will also provide guidance on doses to be used in future studies involving patients with autoimmune diseases.

02

Conditions studied

  • Healthy Chinese Volunteers
03

In context

Lead sponsor

Harbour BioMed (Guangzhou) Co. Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Han Chinese male or female subjects, and his/her biological parents and grandparents are of Han Chinese ethnicity.
  2. Body weight ≥ 50kg with ≥19.0 and \<=24.0 kg/m2 at screening and baseline visit.
  3. Generally, in good health with no abnormalities as determined by medical history, physical examination, 12-lead and clinical laboratory tests.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a total IgG level of \< 700mg/dL at screening.
  2. Subject has an active infection or has had a serious infection within 6 weeks prior to Day -1 or infection requiring oral anti-infective agents within 2 weeks prior to Day-1, or subject had a febrile illness or symptomatic, viral, bacterial, or fungal infection within 1 week prior to admission (Day -1).
  3. History of relevant allergy/ (including allergy to study drug or its ).
  4. Any laboratory values outside the reference range that are of clinical significance according to investigator's clinical judgement.
  5. Subject has estimated ≤ 80 mL/min calculated by Cockcroft Gault formula at screening.
  6. Subject has any abnormality defined in the protocol (a single repeat will be allowed for eligibility determination) at screening or Day -1:
  7. Positive test result at screening.
  8. Positive testing for HBs Antigen and/or a positive antibody test result at screening.
  9. Subject has a positive T-cell interferon-γ release assay (TIGRA) result
  10. Subjects who had immunization within 4 weeks before screening; or subjects who plan to have immunization during the study and within 12 weeks after dosing of the study drug.
  11. For female subjects, positive pregnancy test at screening or Day -1, or planning to become pregnant from screening until 90 days after the dosing of the study drug.
  12. Lactating female subjects.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    HBM9161 340mg

    Drug: HBM9161(HL161BKN)

  • Experimental
    HBM9161 510mg

    Drug: HBM9161(HL161BKN)

  • Experimental
    HBM9161 680mg

    Drug: HBM9161(HL161BKN)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Subcutaneous injection; Single dose on Day 1

  • DrugPlacebo

    Subcutaneous injection; Single dose on Day 1

06

What researchers measure

Primary outcomes

  1. The number [N (%)] of subjects with drug-related AEs

    The number \[N (%)\] of subjects with drug-related AEs

    Time frame: 85 days

07

Study locations

1 site
  • Queen Mary Hospital, Phase 1 Clinical Trials Centre
    Hong Kong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Nov 2019, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jun 3, 2019
StartActual
Jun 3, 2019
Primary completionActual
Nov 6, 2019
CompletionActual
Nov 6, 2019
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03971916
Lead sponsor
Harbour BioMed (Guangzhou) Co. Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2019
Start date
Jun 3, 2019
Primary completion
Nov 6, 2019
Completion
Nov 6, 2019
Last update
Mar 10, 2021

Study contacts

Desmond Yat Hin YAP
principal investigator · Queen Mary Hospital, Phase 1 Clinical Trials Centre

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion